Choose a folder
Scientific Committee meeting drives forward exciting plans for DISCOVER publications in 2018
DISCOVER Scientific Committee members met in London, UK, on 27–28 November to discuss the progress of the study and to plan for future publications.
This is an exciting time for DISCOVER! After the huge efforts by the investigators to collect follow-up data in 2017, this was the first opportunity for members of the Scientific Committee to meet face-to-face to discuss the data. The first insights on the impact of second-line glucose lowering therapies on patient outcomes prompted numerous lively discussions. Scientific Committee members also discussed the publications for 6-month and 1-year follow-up data, including the content for the 2018 congress abstracts and manuscripts. Finally, the Scientific Committee members took the opportunity to discuss the 1-hour scientific session for the IDF 2017 congress in Abu Dhabi to ensure DISCOVER will have the best possible end to the year.
Prof. Linong Ji, a member of the Scientific Committee said: “It was a great pleasure to see you all. We have made tremendous progress in the last year and the study has produced excellent data to improve our knowledge of the treatment of patients with type 2 diabetes all over the world. I am eagerly looking forward to what we can accomplish with DISCOVER in the future.”
Peter Fenici, Senior Global Medical Affairs Leader at AstraZeneca said: “I am very proud of the work that the whole DISCOVER team has put in to organise the operational aspects of the study, and of the investigators for keeping up our excellent patient retention and overall engagement with the study. Keep up the good work!”
The Scientific Committee members remain very excited about the study progress and the possibility to develop insightful publications, which will ultimately contribute to improving patient care. Now, we look forward to seeing the data for the remaining follow-up period!
Approval ID: Z4-8397 Date of preparation: 19/12/2017 Date of expiry: 19/12/2018